Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients

Overview

Reactive or secondary thrombocytosis is defined as abnormally high platelet count (≥4,50,000 platelets per micro-liter) in the absence of chronic myeloproliferative disease. In critically ill patients reactive thrombocytosis is not uncommon during recovery phase and an association has been seen with poor outcome and increased risk of subsequent VTE. However, not all patients with infection respond with thrombocytosis. No study has enumerated the risk factors or predictors of reactive thrombocytosis in critically ill septic patients.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2019

Detailed Description

All patients admitted to intensive care unit of the department of Critical Care Medicine during one year period will be screened for possible inclusion in this study. In this prospective observational study, demographic and clinical characteristics of all ICU patients who fulfill inclusion criteria will be collected along with relevant laboratory tests done for patient management routinely. ICU prognostication scores, i.e., Acute Physiologic and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score will also be recorded. ICU survivors will be followed up in their routine ICU follow up clinic visits. Sample size was estimated at 10% incidence rate of reactive thrombocytes, two sided 95% confidence interval and 4.5% margin of error of the incidence rate, sample size came out to be 171. Finally in this study investigators have targeted to include at least 180 participants. Sample size was estimated using software power analysis and sample size, 2008 (PASS-8).

Clinical Trial Outcome Measures

Primary Measures

  • Reactive or secondary thrombocytosis in critically ill septic patients
    • Time Frame: From date of inclusion until the date of thrombocytosis or date of ICU discharge (death or alive), whichever came first, assessed up to 3 months
    • Reactive or secondary thrombocytosis (≥4,50,000 platelets per micro-liter) due to the sepsis

Participating in This Clinical Trial

Inclusion Criteria

  • All adult (≥18 years) ICU patients with the diagnosis of sepsis will be considered. Exclusion Criteria:

  • Age <18 years – Pregnancy – H/O Malignancy – Thrombocytosis at admission – Primary thrombocytosis – Post-splenectomy – Chronic inflammatory disease (e.g. Connective tissue disorders, IBD, temporal arteritis) – Known immunosupressive condition – Chronic infectious diseases (e.g. tuberculosis, chronic pneumonitis)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sanjay Gandhi Postgraduate Institute of Medical Sciences
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mohan Gurjar, Additional Professor – Sanjay Gandhi Postgraduate Institute of Medical Sciences
  • Overall Official(s)
    • Mohan Gurjar, MD, PDCC, Principal Investigator, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
  • Overall Contact(s)
    • Mohan Gurjar, MD, PDCC, 915222495403, m.gurjar@rediffmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.